Document is current
Any future updates will be listed below
-
Authors
Harris, Michael A. https://orcid.org/0000-0002-9904-4091
Savas, Peter
Virassamy, Balaji
O’Malley, Megan M. R.
Kay, Jasmine https://orcid.org/0009-0009-6673-6604
Mueller, Scott N. https://orcid.org/0000-0002-3838-3989
Mackay, Laura K.
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Loi, Sherene https://orcid.org/0000-0001-6137-9171
- License Information
-
More Information
Article History
Accepted: 31 May 2024
First Online: 5 July 2024
Competing interests
: P.S. receives funding to institution from Roche-Genentech. R.S. reports non-financial support from Merck and Bristol Myers Squibb (BMS), research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS, Astra Zeneca, Daicchii Sankyo and Exact Sciences for advisory boards. S.L. receives research funding to institution from Novartis, Bristol Myers Squibb, MSD, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, Astra Zeneca/Daiichi Sankyo and Seattle Genetics. S.L. has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Myers Squibb, MSD, AstraZeneca–Daiichi Sankyo, Eli Lilly, Pfizer, Gilead Therapeutics, Nektar Therapeutics, PUMA Biotechnologies and Roche-Genentech. S.L. has acted as consultant (paid to institution) to Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca–Daiichi Sankyo, Gilead Sciences, Seattle Genetics, Merck Sharp and Dohme, Eli Lilly and Bristol Myers Squibb. All other authors declare no conflicts.
